Chicago Atlantic Backs Ocular Science with $16.5M Loan
Event summary
- Chicago Atlantic arranged and administered a $16.5M senior secured term loan for Ocular Science, an affiliate of OSRX.
- Ocular Science focuses on compounded ophthalmic products, guided by a 31-member medical advisory board.
- OSRX is an FDA-registered 503B outsourcing facility serving over 9,500 prescribers nationwide.
- The loan aims to strengthen Ocular Science's operating flexibility and support growth initiatives.
The big picture
Chicago Atlantic's $16.5M loan to Ocular Science underscores the growing demand for specialized financing in the biotech sector, particularly in ophthalmology. The deal aligns with industry tailwinds, including an aging population and the need for cost-effective, patient-centric care solutions. With over $3.2B in credit facilities closed, Chicago Atlantic continues to target esoteric industries where traditional capital is scarce.
What we're watching
- Market Expansion
- Whether Ocular Science can leverage the capital to accelerate its nationwide physician relationships and prescriber base.
- Regulatory Compliance
- How OSRX maintains FDA compliance while scaling production to meet growing demand for compounded ophthalmic solutions.
- Operational Efficiency
- The pace at which Ocular Science integrates the loan proceeds to streamline treatment protocols and reduce costs for patients.
Related topics